Patents by Inventor Fabienne Piras

Fabienne Piras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11524069
    Abstract: The invention relates to an immunogenic composition comprising an HCMV gB antigen, an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a Th1-inducing adjuvant. If further relates to the immunogenic composition for use as an HCMV vaccine.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: December 13, 2022
    Assignee: Sanofi Pasteur
    Inventors: Pascal Chaux, Rafaela Dumas, Jean Haensler, Sylvie Pichon, Fabienne Piras-Douce
  • Patent number: 11471521
    Abstract: The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: October 18, 2022
    Assignee: Sanofi Pasteur
    Inventors: Manuel Vangelisti, Nathalie Mantel, Yves Girerd-Chambaz, Fabienne Piras
  • Patent number: 11452772
    Abstract: The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: September 27, 2022
    Assignee: Sanofi Pasteur
    Inventors: Manuel Vangelisti, Nathalie Mantel, Yves Girerd-Chambaz, Fabienne Piras
  • Publication number: 20220047692
    Abstract: The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.
    Type: Application
    Filed: November 5, 2021
    Publication date: February 17, 2022
    Inventors: Manuel Vangelisti, Nathalie Mantel, Yves Girerd-Chambaz, Fabienne Piras
  • Patent number: 11207403
    Abstract: The invention relates to an immunogenic composition comprising an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a TH1-inducing adjuvant. It further relates to the immunogenic composition for use as an HCMV vaccine.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: December 28, 2021
    Assignee: Sanofi Pasteur
    Inventors: Pascal Chaux, Rafaela Dumas, Jean Haensler, Sylvie Pichon, Fabienne Piras-Douce
  • Publication number: 20210154289
    Abstract: The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.
    Type: Application
    Filed: April 2, 2019
    Publication date: May 27, 2021
    Inventors: Manuel Vangelisti, Nathalie Mantel, Yves Girerd-Chambaz, Fabienne Piras
  • Publication number: 20210023202
    Abstract: The invention relates to an immunogenic composition comprising an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a TH1-inducing adjuvant. It further relates to the immunogenic composition for use as an HCMV vaccine.
    Type: Application
    Filed: October 15, 2020
    Publication date: January 28, 2021
    Inventors: Pascal Chaux, Rafaela Dumas, Jean Haensler, Sylvie Pichon, Fabienne Piras-Douce
  • Publication number: 20200276301
    Abstract: The invention relates to an immunogenic composition comprising an HCMV gB antigen, an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a Th1-inducing adjuvant. If further relates to the immunogenic composition for use as an HCMV vaccine.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Inventors: Pascal Chaux, Rafaela Dumas, Jean Haensler, Sylvie Pichon, Fabienne Piras-Douce